Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$1.85 +0.5%	$1.72	$0.66 ▼ $3.00	$172.27M	2.55	1.34 million shs	1.40 million shs
DAWN Day One Biopharmaceuticals	$7.20 +3.2%	$6.62	$5.64 ▼ $16.76	$737.50M	-1.26	1.38 million shs	1.65 million shs
MGTX MeiraGTx	$7.83 -0.3%	$7.67	$3.85 ▼ $8.98	$629.90M	1.25	529,551 shs	310,647 shs
SIGA Siga Technologies	$9.13 +4.3%	$7.16	$4.95 ▼ $9.80	$653.80M	0.94	478,514 shs	861,154 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	+2.22%	-8.00%	-22.36%	+80.39%	-17.49%
DAWN Day One Biopharmaceuticals	+2.50%	+11.68%	+6.24%	+11.32%	-50.85%
MGTX MeiraGTx	+3.84%	-5.76%	-8.61%	+53.92%	+80.46%
SIGA Siga Technologies	-0.34%	+1.98%	+27.74%	+48.05%	-10.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBU Caribou Biosciences	2.9753 of 5 stars	3.5	5.0	0.0	2.4	1.7	0.0
DAWN Day One Biopharmaceuticals	2.4597 of 5 stars	3.6	2.0	0.0	2.5	2.5	0.0
MGTX MeiraGTx	4.4662 of 5 stars	3.5	4.0	4.8	2.0	2.5	0.6
SIGA Siga Technologies	2.0955 of 5 stars	0.0	2.0	0.0	2.5	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	3.00	Buy	$6.67	260.36% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$25.29	251.19% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	206.51% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CRBU, SIGA, MGTX, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$25.00
8/15/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$9.99M	17.24	N/A	N/A	$1.78 per share	1.04
DAWN Day One Biopharmaceuticals	$131.16M	5.62	N/A	N/A	$4.50 per share	1.60
MGTX MeiraGTx	$37.92M	16.61	N/A	N/A	$0.04 per share	195.75
SIGA Siga Technologies	$138.72M	4.71	$0.87 per share	10.49	$2.92 per share	3.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$149.10M	-$1.78	N/A	N/A	N/A	-1,800.93%	-62.35%	-49.65%	11/5/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	10/29/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.04	N/A	20.61	N/A	-415.39%	-314.44%	-63.28%	N/A
SIGA Siga Technologies	$59.21M	$1.13	8.08	7.30	N/A	45.73%	40.52%	35.62%	11/6/2025 (Estimated)

Latest CRBU, SIGA, MGTX, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MGTX MeiraGTx	-$0.52	-$0.48	+$0.04	-$0.48	$8.00 million	$3.69 million
8/12/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	-$0.35	+$0.05	-$0.58	$1.64 million	$2.67 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	6.66	6.66
DAWN Day One Biopharmaceuticals	N/A	9.65	9.53
MGTX MeiraGTx	26.29	0.88	1.51
SIGA Siga Technologies	N/A	10.09	8.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
DAWN Day One Biopharmaceuticals	87.95%
MGTX MeiraGTx	67.48%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	8.28%
DAWN Day One Biopharmaceuticals	6.20%
MGTX MeiraGTx	7.50%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	100	93.12 million	85.41 million	Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
MGTX MeiraGTx	300	80.45 million	74.41 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable

CRBU, SIGA, MGTX, and DAWN Headlines

Recent News About These Companies

First Wilshire Securities Management Inc. Has $8.70 Million Stock Position in Siga Technologies Inc. $SIGA

August 21 at 6:06 AM | marketbeat.com

SIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA News

August 20 at 3:04 AM | seekingalpha.com

Siga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?

August 15, 2025 | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Rating Increased to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-Buy

August 10, 2025 | marketbeat.com

SIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)

August 8, 2025 | finance.yahoo.com

Siga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's Why

August 7, 2025 | marketbeat.com

SIGA (SIGA) Q2 Revenue Soars 272%

August 7, 2025 | theglobeandmail.com

Siga Technologies (NASDAQ:SIGA) Issues Earnings Results

August 6, 2025 | marketbeat.com

SIGA Technologies (SIGA) Reports Significant Earnings Decline

August 6, 2025 | finance.yahoo.com

SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding

August 6, 2025 | msn.com

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 5, 2025 | globenewswire.com

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 29, 2025 | globenewswire.com

Royce & Associates LP Has $4.16 Million Holdings in Siga Technologies Inc. (NASDAQ:SIGA)

July 28, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know

July 24, 2025 | zacks.com

Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 24, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15, 2025 | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU, SIGA, MGTX, and DAWN Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$1.85 +0.01 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.83 -0.02 (-1.03%)

As of 06:31 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Day One Biopharmaceuticals NASDAQ:DAWN

$7.20 +0.22 (+3.15%)

Closing price 04:00 PM Eastern

Extended Trading

$7.14 -0.06 (-0.82%)

As of 05:27 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

MeiraGTx NASDAQ:MGTX

$7.83 -0.02 (-0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$7.81 -0.02 (-0.26%)

As of 04:47 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Siga Technologies NASDAQ:SIGA

$9.13 +0.38 (+4.34%)

Closing price 04:00 PM Eastern

Extended Trading

$9.01 -0.13 (-1.37%)

As of 06:58 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time